Published in Nat Biotechnol on February 01, 2016
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell (2016) 1.08
Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nat Biotechnol (2016) 1.06
A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods (2016) 0.92
Genome editing in cardiovascular diseases. Nat Rev Cardiol (2016) 0.86
Customizing the genome as therapy for the β-hemoglobinopathies. Blood (2016) 0.85
CRISPR: a versatile tool for both forward and reverse genetics research. Hum Genet (2016) 0.82
CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report. Arterioscler Thromb Vasc Biol (2016) 0.82
A universal system to select gene-modified hepatocytes in vivo. Sci Transl Med (2016) 0.82
The present and future of genome editing in cancer research. Hum Genet (2016) 0.81
A CRISPR Path to Engineering New Genetic Mouse Models for Cardiovascular Research. Arterioscler Thromb Vasc Biol (2016) 0.81
In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models. Mol Ther (2017) 0.79
Increased and prolonged human norovirus infection in RAG2/IL2RG deficient gnotobiotic pigs with severe combined immunodeficiency. Sci Rep (2016) 0.79
CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector. Mol Ther Nucleic Acids (2016) 0.79
The Advancement of the Emerging Field of RNA Nanotechnology. ACS Nano (2017) 0.77
Non-viral delivery of genome-editing nucleases for gene therapy. Gene Ther (2016) 0.77
In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing. Arterioscler Thromb Vasc Biol (2017) 0.76
Future of rAAV gene therapy: Platform for RNAi, Gene Editing and Beyond. Hum Gene Ther (2017) 0.76
A Self-restricted CRISPR System to Reduce Off-target Effects. Mol Ther (2016) 0.75
Technological advances in precision medicine and drug development. Expert Rev Precis Med Drug Dev (2016) 0.75
Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich Ataxia. Gene Ther (2016) 0.75
Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice. Nat Commun (2017) 0.75
Synthetically controlling dendrimer flexibility improves delivery of large plasmid DNA. Chem Sci (2017) 0.75
Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev (2016) 0.75
In Vivo Delivery Systems for Therapeutic Genome Editing. Int J Mol Sci (2016) 0.75
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther (2017) 0.75
Prospects and challenges of CRISPR/Cas genome editing for the study and control of neglected vector-borne nematode diseases. FEBS J (2016) 0.75
A non-viral CRISPR/Cas9 delivery system for therapeutic gene targeting in vivo. Cell Res (2017) 0.75
GUIDEseq: a bioconductor package to analyze GUIDE-Seq datasets for CRISPR-Cas nucleases. BMC Genomics (2017) 0.75
Genome editing for inborn errors of metabolism: advancing towards the clinic. BMC Med (2017) 0.75
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles. Mol Ther Nucleic Acids (2016) 0.75
Genome and Epigenome Editing in Mechanistic Studies of Human Aging and Aging-Related Disease. Gerontology (2016) 0.75
Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering. Elife (2017) 0.75
In vivo gene therapy potentials of CRISPR-Cas9. Gene Ther (2016) 0.75
An episomal CRISPR/Cas9 system to derive vector-free gene modified mammalian cells. Protein Cell (2016) 0.75
Gene Editing and Genetic Lung Disease: Basic Research Meets Therapeutic Application. Am J Respir Cell Mol Biol (2016) 0.75
Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. Sci Rep (2017) 0.75
CRISPR/Cas9 - Mediated Precise Targeted Integration In Vivo Using a Double Cut Donor with Short Homology Arms. EBioMedicine (2017) 0.75
CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10. Mol Ther (2017) 0.75
Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc Natl Acad Sci U S A (2017) 0.75
Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci U S A (2017) 0.75
Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch. Nucleic Acids Res (2017) 0.75
CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion. Genome Biol (2017) 0.75
Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett (2016) 0.75
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol (2013) 19.99
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol (2013) 18.01
Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science (2014) 10.43
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell (2013) 9.55
CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol (2014) 9.18
Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell (2010) 8.79
Cas9 as a versatile tool for engineering biology. Nat Methods (2013) 6.87
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol (2014) 5.71
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol (2014) 5.69
In vivo genome editing using Staphylococcus aureus Cas9. Nature (2015) 5.26
Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol (2014) 5.07
Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol (2007) 5.04
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
Gene conversion tracts from double-strand break repair in mammalian cells. Mol Cell Biol (1998) 4.46
Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A (2010) 4.25
Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell (2013) 3.97
ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics (2010) 3.47
Saturation editing of genomic regions by multiplex homology-directed repair. Nature (2014) 3.30
Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell (2013) 3.30
CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature (2014) 3.28
Non-viral vectors for gene-based therapy. Nat Rev Genet (2014) 3.04
Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science (2014) 2.93
Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol (2015) 2.77
Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol (2014) 2.75
State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet (2011) 2.71
In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol (2014) 2.51
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol (2011) 2.43
Therapeutic genome editing: prospects and challenges. Nat Med (2015) 2.42
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol (2015) 1.71
A co-CRISPR strategy for efficient genome editing in Caenorhabditis elegans. Genetics (2014) 1.60
Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature (2014) 1.57
Mfge8 is critical for mammary gland remodeling during involution. Mol Biol Cell (2005) 1.53
Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc (2012) 1.50
Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology (2010) 1.41
Canonical and atypical E2Fs regulate the mammalian endocycle. Nat Cell Biol (2012) 1.37
Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1. Proc Natl Acad Sci U S A (2001) 1.28
Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human. Cancer Gene Ther (2008) 1.13
CRISPRseek: a bioconductor package to identify target-specific guide RNAs for CRISPR-Cas9 genome-editing systems. PLoS One (2014) 1.11
A fast and sensitive alternative for β-galactosidase detection in mouse embryos. Development (2012) 1.04
In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. Nat Biotechnol (2015) 0.96
Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. Nano Lett (2015) 0.93
DNA-binding-domain fusions enhance the targeting range and precision of Cas9. Nat Methods (2015) 0.88
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol (2014) 5.71
Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery. Nat Methods (2015) 0.96
DNA-binding-domain fusions enhance the targeting range and precision of Cas9. Nat Methods (2015) 0.88
Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. Mol Ther (2015) 0.83
CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector. Mol Ther Nucleic Acids (2016) 0.79
FXR1 regulates transcription and is required for tumor growth in TP53 homozygous deletion human cancers. Elife (2017) 0.75
Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope. J Virol (2017) 0.75
Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol (2017) 0.75
CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector. Mol Ther Nucleic Acids (2016) 0.75